Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R G Wilcox

Showing results (61-70 of 80) with videos related to

Pageof 8
Sort By:
Heart (British Cardiac Society)|September 17, 2002
Management and outcome of patients with atrial fibrillation during acute myocardial infarction: the GUSTO-III experience. Global use of strategies to open occluded coronary arteriesC-K Wong, H D White, R G Wilcox, et al.
Diabetes, Obesity & Metabolism|April 5, 2011
High-density lipoprotein-cholesterol and not HbA1c was directly related to cardiovascular outcome in PROactiveE Ferrannini, D J Betteridge, J A Dormandy, et al.
Journal of the American College of Cardiology|July 1, 1997
Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary ArteriesK H Mak, D J Moliterno, C B Granger, et al.
European Heart Journal|August 21, 2001
Geographic variation in patient and hospital characteristics, management, and clinical outcomes in ST-elevation myocardial infarction treated with fibrinolysis. Results from InTIME-IIR P Giugliano, J Llevadot, R G Wilcox, et al.
European Journal of Emergency Medicine : Official Journal of the European Society for Emergency Medicine|January 27, 1999
Prospective use of platelet glycoprotein IIb/IIIa receptor blockers in the emergency department settingW B Gibler, R G Wilcox, C Bode, et al.
Journal of the American College of Cardiology|November 1, 1995
Evaluation of paradoxic beneficial effects of smoking in patients receiving thrombolytic therapy for acute myocardial infarction: mechanism of the "smoker's paradox" from the GUSTO-I trial, with angiographic insights. Global Utilization of Streptokinase and Tissue-Plasminogen Activator for Occluded Coronary ArteriesG I Barbash, J Reiner, H D White, et al.
Annals of Emergency Medicine|December 2, 1998
Prospective use of glycoprotein IIb/IIIa receptor blockers in the emergency department settingW B Gibler, R G Wilcox, C Bode, et al.
American Heart Journal|February 26, 2000
Cigarette smoking status and outcome among patients with acute coronary syndromes without persistent ST-segment elevation: effect of inhibition of platelet glycoprotein IIb/IIIa with eptifibatide. The PURSUIT trial investigatorsD Hasdai, D R Holmes, D A Criger, et al.
European Heart Journal|December 5, 2000
Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation; a phase II studyK M Akkerhuis, K L Neuhaus, R G Wilcox, et al.
British Medical Journal (Clinical Research Ed.)|November 8, 1986
Trial of early nifedipine in acute myocardial infarction: the Trent studyR G Wilcox, J R Hampton, D C Banks, et al.
Pageof 8

Showing results (61-70 of 80) with videos related to

Sort By:
Pageof 8
Heart (British Cardiac Society)|September 17, 2002
Management and outcome of patients with atrial fibrillation during acute myocardial infarction: the GUSTO-III experience. Global use of strategies to open occluded coronary arteriesC-K Wong, H D White, R G Wilcox, et al.
Diabetes, Obesity & Metabolism|April 5, 2011
High-density lipoprotein-cholesterol and not HbA1c was directly related to cardiovascular outcome in PROactiveE Ferrannini, D J Betteridge, J A Dormandy, et al.
Journal of the American College of Cardiology|July 1, 1997
Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary ArteriesK H Mak, D J Moliterno, C B Granger, et al.
European Heart Journal|August 21, 2001
Geographic variation in patient and hospital characteristics, management, and clinical outcomes in ST-elevation myocardial infarction treated with fibrinolysis. Results from InTIME-IIR P Giugliano, J Llevadot, R G Wilcox, et al.
European Journal of Emergency Medicine : Official Journal of the European Society for Emergency Medicine|January 27, 1999
Prospective use of platelet glycoprotein IIb/IIIa receptor blockers in the emergency department settingW B Gibler, R G Wilcox, C Bode, et al.
Journal of the American College of Cardiology|November 1, 1995
Evaluation of paradoxic beneficial effects of smoking in patients receiving thrombolytic therapy for acute myocardial infarction: mechanism of the "smoker's paradox" from the GUSTO-I trial, with angiographic insights. Global Utilization of Streptokinase and Tissue-Plasminogen Activator for Occluded Coronary ArteriesG I Barbash, J Reiner, H D White, et al.
Annals of Emergency Medicine|December 2, 1998
Prospective use of glycoprotein IIb/IIIa receptor blockers in the emergency department settingW B Gibler, R G Wilcox, C Bode, et al.
American Heart Journal|February 26, 2000
Cigarette smoking status and outcome among patients with acute coronary syndromes without persistent ST-segment elevation: effect of inhibition of platelet glycoprotein IIb/IIIa with eptifibatide. The PURSUIT trial investigatorsD Hasdai, D R Holmes, D A Criger, et al.
European Heart Journal|December 5, 2000
Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation; a phase II studyK M Akkerhuis, K L Neuhaus, R G Wilcox, et al.
British Medical Journal (Clinical Research Ed.)|November 8, 1986
Trial of early nifedipine in acute myocardial infarction: the Trent studyR G Wilcox, J R Hampton, D C Banks, et al.
Pageof 8